* previous history of severe allergy or sensitivity to inhalation allergens; * women are breastfeeding, pregnant, or planning to become pregnant during the study period; * participated in clinical trials of sars-cov-2 neutralizing antibody injections within 180 days prior to screening or clinical trials of other drugs within 4 weeks prior to screening; * subjects unable to cooperate with nasal spray inhalation; * body temperature at baseline (day 0)\>37.0℃; * had a severe neurological disorder (epilepsy, convulsions or convulsions) or psychosis, and have a family history of psychosis; * the researchers determined that the subjects had a serious chronic medical condition that could interfere with the conduct or completion of the study; * according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

* previous history of severe allergy or sensitivity to inhalation allergens; * women are breastfeeding, pregnant, or planning to become pregnant during the study period; * participated in clinical trials of sars-cov-2 neutralizing antibody injections within 180 days prior to screening or clinical trials of other drugs within 4 weeks prior to screening; * subjects unable to cooperate with nasal spray inhalation; * body temperature at baseline (day 0)\>37.0℃; * had a severe neurological disorder (epilepsy, convulsions or convulsions) or psychosis, and have a family history of psychosis; * the researchers determined that the subjects had a serious chronic medical condition that could interfere with the conduct or completion of the study; * according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

previous history of severe allergy or sensitivity to inhalation allergens; women are breastfeeding, pregnant, or planning to become pregnant during the study period; participated in clinical trials of sars-cov-2 neutralizing antibody injections within 180 days prior to screening or clinical trials of other drugs within 4 weeks prior to screening; subjects unable to cooperate with nasal spray inhalation; body temperature at baseline (day 0)>37.0℃; had a severe neurological disorder (epilepsy, convulsions or convulsions) or psychosis, and have a family history of psychosis; the researchers determined that the subjects had a serious chronic medical condition that could interfere with the conduct or completion of the study; according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

previous history of severe allergy or sensitivity to inhalation allergens; women are breastfeeding, pregnant, or planning to become pregnant during the study period; participated in clinical trials of sars-cov-2 neutralizing antibody injections within 180 days prior to screening or clinical trials of other drugs within 4 weeks prior to screening; subjects unable to cooperate with nasal spray inhalation; body temperature at baseline (day 0)>37.0℃; had a severe neurological disorder (epilepsy, convulsions or convulsions) or psychosis, and have a family history of psychosis; the researchers determined that the subjects had a serious chronic medical condition that could interfere with the conduct or completion of the study; according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.